Adaptimmune raises US$100m
Oxford-based Adaptimmune Therapeutics plc has raised US$100m in a registered direct offering of American Depositary Shares (ADS).
ADVERTISEMENT
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1996 entries already.
Entries by Thomas Gabrielczyk
CAR-Ts: Novartis wins UK
The NHS England announces it will reimburse Novartis CAR-T cell therapy Kymriah as treatment for children with B cell acute lymphoblastic leukemia (ALL) that are refractory, in relapse post-transplant or in second or later relapse.
Evox raises €37m in Series B round
Exosome drug delivery specialist Evox Therapeutics Ltd has closed a €37.1m (£35.5m) Series B financing round led by Redmile Group and significant contributions from GV (Google Ventures) and Cowen Healthcare Investments.
Sanofi gets the EUs ok for caplacizumab
The EU approved Sanofis Cablivi (caplacizumab) as the first antibody therapeutic to treat acquired thrombotic thrombocytopenic purpura (aTTP) on Friday.
Cancer drug cures orphan disease skin damage
An FDA-approved cancer drug stops light sensitivity of the skin in Cockayne syndrome (CS), an ultra-rare hereditary disease characterised by premature aging, German researchers report.
Germany to pump €1bn into breakthrough innovation
Germanys government announced that it will create an agency for breakthrough ("jump") innovation to foster technology transfer of risky research projects with high market potential into products.
Urovant Sciences licenses OAB gene therapy
Urovant Sciences has licensed the global commercialisation rights for Ion Channel Innovations gene therapy hMaxi-K for patients with overactive bladder (OAB) symptoms who have failed oral pharmacologic therapy.
Roche and Affimed in US$5bn cancer deal
Roches US arm Genentech has licenced Affimed NVs ROCK platform to add multivalent antibodies, which could activate the innate immune system, to its cancer pipeline.
Foundation launches £30m award
The British Heart Foundation (BHF) will tender £30m (€33.2m) to tackle the suffering and devastation caused by heart and circulatory diseases.
Closing the gap in haemophilia therapy
About 25% of the people who suffer from haemophilia A have no therapeutic options, because their immune system forms antibodies against clotting products that can stop bleeding. Researchers and companies in the growing US$15.8bn haemophilia market are feverishly exploring new ways to identify patients at risk and offer them alternative treatments. A series of mergers and acquisitions have changed the playing field for established markets and players.